NEW YORK (Reuters Health)—Bone mineral density (BMD), particularly lumbar BMD, may not reliably indicate the presence of asymptomatic vertebral fragility fractures in post-menopausal women, new findings suggest. In a study online May 9 in Bone, Italian researchers found such fractures were common among women seen at an osteoporosis clinic, yet the vast majority had not…
Articles by Natasha Yetman
Larger Weight Loss Tied to Greater Improvements in Arthritic Knees
(Reuters Health)—Obese people with knee osteoarthritis (OA) may find greater symptom relief when they lose larger amounts of weight, a recent study suggests. Researchers examined data on 240 obese adults with pain from knee OA who were participating in an 18-month experiment to see how diet alone or diet plus exercise affected their health. Participants…
U.S. Justice Department Says Obamacare Individual Mandate Unconstitutional
WASHINGTON (Reuters)—The U.S. Department of Justice (DOJ) said on Thursday that the part of Obamacare requiring individuals to have health insurance is unconstitutional, an unusual move that could lead to stripping away some of the most significant and popular parts of the law. In a brief filed in a federal court in Texas, the department…
Hip Bone Deterioration May Differ Significantly Between Men & Women
NEW YORK (Reuters Health)—Various image analysis techniques show sex-specific patterns of bone deterioration at the hip, suggesting that men and women should be assessed differently for hip fracture risk, researchers say. “One major contribution of this work is the integration of data-driven computational anatomy approaches, which showed that proximal femur fragility linked to fracture seems…
Fed Up with Rising Costs, Big U.S. Firms Dig Into Healthcare
SAN JOSE, Calif., (Reuters)—At its Silicon Valley headquarters, network gear maker Cisco Systems Inc. is going to unusual lengths to take control of the relentless increase in its U.S. healthcare costs. The company is among a handful of large American employers who are getting more deeply involved in managing their workers’ health instead of looking…
AbbVie’s RA Drug Succeeds in Late Stage Study
(Reuters)—Abbvie Inc. says its experimental drug met the main goal of halting progression of moderate to severe rheumatoid arthritis (RA) in a late-stage trial. The drug, upadacitinib, was tested as a monotherapy in patients who have not been treated with chemotherapy agent methotrexate. Upadacitinib, which belongs to a class of drugs known as JAK inhibitors,…
Research Shows High Adherence to Performance Measures for RA Cohort
New research examines the adherence rates for system-level performance measures in Canada. Using data from the Canadian Early Arthritis Cohort that spanned eight years, researchers determined the percentage of RA patients seen in yearly follow-up with the number of gaps between visits, the percentage of RA patients treated with a disease-modifying anti-rheumatic drug and number days from diagnosis to the initiation of treatment. The results: High adherence to system-level performance measures was found in this early RA cohort, with small declines in performance with the increasing length overtime…
Current Graduate Medical Education Can’t Meet Future Needs
In 2005, an ACR Workforce Study estimated the adult rheumatology workforce to be 4,946 providers and projected growth of only 1.2% by 2025, resulting in a projected deficit of 2,576 rheumatologists considering the estimated need. According to the 2015 Workforce Study, between 2005 and 2015, the percentage of internal medicine residents entering rheumatology has remained…
Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections
NEW YORK (Reuters Health)—Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest. “It’s reassuring for mothers who need to take these medications during pregnancy,” Evelyne Vinet, MD, of McGill University Health Center in…
Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 98
- Next Page »